Olopatadine
- Generic Name
- Olopatadine
- Brand Names
- Pataday, Patanase, Patanol, Pazeo, Ryaltris, Opatanol
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23NO3
- CAS Number
- 113806-05-6
- Unique Ingredient Identifier
- D27V6190PM
- Background
Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of doxepin, which has a minimal anti-allergic activity. Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and allergic reac...
- Indication
Olopatadine is indicated for the symptomatic treatment of ocular itching associated with allergic conjunctivitis as ophthalmic solution.
As a nasal spray, as a monotherapy or in combination with mometasone furoate, olopatadine is indicated for the symptomatic relief of seasonal allergic rhinitis in patients 12 years of age and older.
- Associated Conditions
- Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Seasonal Allergic Rhinitis, Moderate, severe Seasonal Allergic Rhinitis, Ocular effects
- Associated Therapies
- -
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
- Conditions
- Interventions
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- ORA, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03320434
- Locations
- 🇺🇸
Andover Eye Associates, Andover, Massachusetts, United States
Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1025
- Registration Number
- NCT02478398
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
- Conditions
- Interventions
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 240
- Registration Number
- NCT02161146
A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
- Conditions
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Mati Therapeutics Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01287338
- Locations
- 🇨🇦
Cetero Research, Toronto, Ontario, Canada
Olopatadine Eye Drops and Allergy Skin Testing
- Conditions
- Interventions
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT00775658
- Locations
- 🇺🇸
Vanderbilt Asthma, Sinus and Allergy Program Research, Nashville, Tennessee, United States
A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2008-04-09
- Lead Sponsor
- Greiner, Jack V., OD DO PhD
- Target Recruit Count
- 60
- Registration Number
- NCT00655109
- Locations
- 🇺🇸
Ophthalmic Research Associates, Inc, North Andover, Massachusetts, United States
Effect of Olopatadine on Allergic Tear Mediators
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 21
- Registration Number
- NCT00609128
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 79
- Registration Number
- NCT00534794
- Locations
- 🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.